Noxafil (Posaconazole)

Posaconazole, the active ingredient in Noxafil, is an azole antifungal presented as an oral tablet for systemic use. It is employed to prevent and treat serious fungal infections, particularly in patients with weakened immune systems such as those undergoing chemotherapy or stem‑cell transplantation.

GNH USA supplies Noxafil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics across multiple regions worldwide, with a focus on quality assurance and regulatory compliance and timely delivery to meet patient needs.

Posaconazole is an azole antifungal used to prevent and treat invasive fungal infections in high‑risk patient groups.

- Invasive Aspergillosis Prophylaxis: prevents infection in neutropenic patients undergoing chemotherapy or stem‑cell transplantation. - Treatment of Invasive Aspergillosis: provides a therapeutic option when first‑line agents are unsuitable or resistance is present. - Oropharyngeal Candidiasis: treats refractory oral yeast infections in immunocompromised individuals.

Posaconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset. - Diarrhea: loose stools. - Elevated liver enzymes: mild increase in ALT/AST.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury. - QT interval prolongation: risk of cardiac arrhythmia. - Severe hypersensitivity reactions: rash, fever, or anaphylaxis.

When using Posaconazole, several precautionary measures should be observed to ensure safety and efficacy.

- Hepatic impairment: monitor liver function tests regularly. - Renal impairment: assess kidney function and adjust monitoring as needed. - QT prolongation risk: obtain baseline ECG and monitor if risk factors present. - Drug interactions: review concomitant medications for potential CYP3A4 interactions. - Pregnancy and lactation: avoid use unless benefit outweighs potential risk. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Posaconazole interacts with several medicines; understanding the interaction level guides clinical management.

Major Interactions (Avoid): - Rifampin: markedly reduces posaconazole exposure, compromising efficacy. - St. John’s wort: induces metabolism leading to subtherapeutic levels.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase posaconazole concentrations, may require dose adjustment. - H2‑receptor antagonists (e.g., cimetidine): raise posaconazole levels. - Warfarin: may enhance anticoagulant effect, monitor INR closely.